[DGlp1,DPhe2,DTrp3,6]-LH-RH
Modify Date: 2024-01-10 08:52:03
![[DGlp1,DPhe2,DTrp3,6]-LH-RH Structure](https://www.chemsrc.com/caspic/058/68059-94-9.png)
[DGlp1,DPhe2,DTrp3,6]-LH-RH structure
|
Common Name | [DGlp1,DPhe2,DTrp3,6]-LH-RH | ||
|---|---|---|---|---|
| CAS Number | 68059-94-9 | Molecular Weight | 1321.48000 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C67H84N16O13 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS08 |
Signal Word | Danger | |
Use of [DGlp1,DPhe2,DTrp3,6]-LH-RH[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH acts as a GnRH receptor antagonist[1]. |
| Name | [DGlp1,DPhe2,DTrp3,6]-LH-RH |
|---|---|
| Synonym | More Synonyms |
| Description | [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH acts as a GnRH receptor antagonist[1]. |
|---|---|
| Related Catalog | |
| Target |
GnRH receptor[1] |
| In Vitro | [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH (1 μM), together with LH-RH and FSH, blocks the inhibition of FSH-induced steroidogenesis in rat ovary granulosa cells[3]. |
| In Vivo | [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH (1.25 and 2.5 mg, subcutaneous injection, b.i.d, for 7 days) prolongs pregnancy in rats[1]. [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH (250 μg) inhibits ovulation by 100% in rats[2]. |
| Molecular Formula | C67H84N16O13 |
|---|---|
| Molecular Weight | 1321.48000 |
| Exact Mass | 1320.64000 |
| PSA | 459.24000 |
| LogP | 4.47690 |
| Symbol |
GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H360 |
| Precautionary Statements | P201-P308 + P313 |
| Personal Protective Equipment | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | T: Toxic; |
| Risk Phrases | R60 |
| Safety Phrases | 53-22-36/37/39-45 |
| RIDADR | NONH for all modes of transport |
|
Characterization of Leydig cell gonadotropin-releasing hormone binding sites utilizing radiolabeled agonist and antagonist.
Peptides 3(5) , 789-92, (1982) Gonadotropin-releasing hormone (GnRH) binding sites in intact Leydig cells and in membrane preparations were investigated using 125I-labeled GnRH agonist and antagonist. Binding was saturable and invo... |
|
|
Role of lipids in gonadotropin releasing hormone agonists and antagonist binding to rat pituitary.
Biochem. Biophys. Res. Commun. 105(1) , 8-13, (1982) Digestion of pituitary membranes with phospholipase A 2 and phospholipase C abolished, in a dose responsive manner, the specific binding of gonadotropin releasing hormone agonist and antagonist. These... |
|
|
LH-RH analogue acts as substance P antagonist by inhibiting spinal cord vasomotor responses.
Brain Res. 337(2) , 357-61, (1985) Intrathecal injections of the luteinizing hormone-releasing hormone (LH-RH) analogue, [D-pGlu1-D-Phe2-D-Trp3,6]-LH-RH caused dose-dependent decreases in mean arterial blood pressure in anesthetized ra... |
| D-pglu1,D-phe2,D-trp3,6-luteinizing*hormone relea |
| pglu(1)-phe(2)-trp(3,6)-lhr |
| LHRH,pGlu(1)-Phe(2)-Trp(3,6) |
| [D-PGLU1,D-PHE2,D-TRP3,6]-LH-RH |
| [D-PYR1,D-PHE2,D-TRP3,6]-LH-RH (HUMAN) |
| (D-PYR1,D-PHE2,D-TRP3,6)-LHRH |
| DGLP-DPHE-DTRP-SER-TYR-DTRP-LEU-ARG-PRO-GLY-NH2 |
| [D-PYROGLU1,D-PHE2,D-TRP3,6]-LH-RH |
| (D-Pyr1,D-Phe2,D-Trp3 |